Cytokine profile and pathology in human leishmaniasis by Jesus, Amélia Maria Ribeiro de et al.
143
Braz J Med Biol Res 31(1) 1998
Cytokine profile and pathology in human leishmaniasisBrazilian Journal of Medical and Biological Research (1998) 31: 143-148
ISSN 0100-879X
Cytokine profile and pathology
in human leishmaniasis
Serviço de Imunologia, Hospital UniversitÆrio Prof. Edgard Santos,
Universidade Federal da Bahia, Salvador, BA, Brasil
A. Ribeiro-de-Jesus,
R.P. Almeida,
H. Lessa, O. Bacellar and
E.M. Carvalho
Abstract
The clinical spectrum of leishmaniasis and control of the infection are
influenced by the parasite-host relationship. The role of cellular
immune responses of the Th1 type in the protection against disease in
experimental and human leishmaniasis is well established. In humans,
production of IFN-γ is associated with the control of infection in
children infected by Leishmania chagasi. In visceral leishmaniasis, an
impairment in IFN-γ production and high IL-4 and IL-10 levels (Th2
cytokines) are observed in antigen-stimulated peripheral blood mono-
nuclear cells (PBMC). Moreover, IL-12 restores IFN-γ production and
enhances the cytotoxic response. IL-10 is the cytokine involved in
down-regulation of IFN-γ production, since anti-IL-10 monoclonal
antibody (mAb) restores in vitro IFN-γ production and lymphoprolif-
erative responses, and IL-10 abrogates the effect of IL-12. In cutane-
ous and mucosal leishmaniasis, high levels of IFN-γ are found in L.
amazonensis-stimulated PBMC. However, low or absent IFN-γ levels
were observed in antigen-stimulated PBMC from 50% of subjects
with less than 60 days of disease (24 – 26 pg/ml). This response was
restored by IL-12 (308 – 342 pg/ml) and anti-IL-10 mAb (380 – 245
pg/ml) (P<0.05). Later during the disease, high levels of IFN-γ and
TNF-α are produced both in cutaneous and mucosal leishmaniasis.
After treatment there is a decrease in TNF-α levels (366 – 224 pg/ml
before treatment vs 142 – 107 pg/ml after treatment, P = 0.02).
Although production of IFN-γ and TNF-α might be involved in the
control of parasite multiplication in the early phases of Leishmania
infection, these cytokines might also be involved in the tissue damage
seen in tegumentary leishmaniasis.
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Leishmaniasis is a parasitic infection
caused by a protozoan from the Trypanoso-
matidae family, genus Leishmania. Four clini-
cal forms of the disease have been described:
visceral, cutaneous, mucosal and diffuse cu-
taneous leishmaniasis (1,2). This clinical
spectrum of the disease is mostly related to
different Leishmania species (1-5), but the
immunological responses to the parasite are
certainly an important determinant of the
clinical outcome of Leishmania  infection
(6). For instance, it has been demonstrated
that the prevalence of serological conversion
in an endemic area of visceral leishmaniasis
is higher than the prevalence of disease (7).
This finding suggests that there are subjects
that are infected and can control the disease.
It is known from studies on experimental
models of leishmaniasis that the control of
Leishmania infection is dependent on T cell
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responses. The role of Th1 or Th2 cell acti-
vation in determining resistance and suscep-
tibility to leishmaniasis has been well dem-
onstrated in two experimental hosts: the sus-
ceptible BALB/c mouse and the resistant
C3H/HeN mouse infected with L. major  (8-
10). While BALB/c mice develop a Th2
response after infection with L. major and
have severe and progressive disease, C3H/
HeN mice develop a Th1 type of response,
with interferon-gamma (IFN-γ) production,
are able to control Leishmania multiplica-
tion and have a self-limited disease (10). In
these animals, treatment with anti-IL-4 mon-
oclonal antibody (mAb) at the time of infec-
tion makes BALB/c mice able to control
leishmaniasis (11) while treatment of C3H/
HeN animals with anti-IFN-γ mAb is associ-
ated with progression of the infection and
severe disease (12). In humans, the strongest
evidence that production of IFN-γ is involved
in the control of Leishmania infection comes
from a longitudinal study evaluating lym-
phoproliferative response and IFN-γ produc-
tion by peripheral blood mononuclear cells
(PBMC) from serum-converting children
from an endemic area of visceral leishmani-
asis. In that study, it was demonstrated that,
upon Leishmania chagasi infection, chil-
dren whose Leishmania antigen-stimulated
PBMC produce IFN-γ will control the infec-
tion, while children who have a poor IFN-γ
production will progress to visceral leish-
maniasis (13). These observations clearly
indicate that absence or poor IFN-γ produc-
tion is a marker of susceptibility to visceral
leishmaniasis. Although it is likely that sev-
eral mechanisms may participate in the in-
ability of lymphocytes from visceral leish-
maniasis patients to produce this cytokine,
one important point is related to the imbal-
ance of cytokines produced in response to
Leishmania antigens, i.e., high production
of IL-4 and IL-10 and low IL-2 and IFN-γ
production (14-18). Although lymphocytes
from patients with visceral leishmaniasis have
a strong expression of mRNA for IL-4 (16,18)
and sera from visceral leishmaniasis patients
have high IL-4 levels (14), there is no evi-
dence that IL-4 is involved in the down-
regulation of the Th1 type of response in
human leishmaniasis. For instance, in vitro
addition of mAb against IL-4 did not restore
the lymphocyte proliferative response or IFN-
γ production in L. chagasi-stimulated PBMC
from visceral leishmaniasis patients (18).
Interleukin-4 also did not suppress lympho-
cyte proliferative response or IFN-γ produc-
tion in subjects cured of leishmaniasis. Pa-
tients with visceral leishmaniasis have in-
creased expression of mRNA for IL-10 in
bone marrow and lymph node cells and high
levels of IL-10 in L. chagasi-stimulated
PBMC supernatants (15,16,18). Moreover,
the addition of mAb to anti-IL-10 restores
lymphocyte proliferative response and IFN-
γ production in PBMC from visceral leish-
maniasis patients (15,18). In visceral leish-
maniasis, there is also an inability of PBMC
to produce IL-12 (19) and restoration of
IFN-γ production and lymphocyte prolifera-
tive response can be achieved by IL-12 addi-
tion (19,20). IL-12 also enhances the cyto-
toxic response, a function that is suppressed
in visceral leishmaniasis patients (20). The
demonstration that IL-10 abrogates the ef-
fect of IL-12 in inducing IFN-γ production in
L. chagasi-stimulated PBMC from visceral
leishmaniasis patients strongly suggests that
IL-10 is the major cytokine involved in the
progression of Leishmania infection to vis-
ceral disease (20). Interleukin-10 blocks Th1
activation and consequently a cytotoxic re-
sponse by down-regulating IL-12 and IFN-γ
production. Additionally, since IL-10 also
inhibits macrophage activation (21) it de-
creases the ability of these cells to kill Leish-
mania.
In contrast to visceral leishmaniasis, pa-
tients with cutaneous and mucosal leish-
maniasis due to L. braziliensis infection have
a strong T cell response, characterized by a
high lymphocyte proliferative response to
Leishmania antigens and IFN-γ production
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(22-25). Delayed-type hypersensitivity to
Leishmania antigen is also present in these
patients and the intradermal skin test is usu-
ally employed for the diagnosis of cutaneous
and mucosal leishmaniasis. Since IFN-γ, a
major cytokine associated with Leishmania
killing, is produced during L. braziliensis
infection, the reasons why such patients de-
velop disease are not clear. The possibility
that immunological responses may be al-
tered in such patients at the site of the lesion
is usually considered. However, immuno-
logical studies in cells from tissues of leish-
maniasis patients have shown an immune
response pattern similar to that seen in PBMC,
with evidence of a Th0 or Th1/Th2 mixed
cytokine pattern (26,27). Some differences
were found in the cytokine profile when
patients with lesions of short duration were
compared with those with old lesions. Pa-
tients with chronic lesions show a strong
expression of pro-inflammatory cytokines
such as TNF-α (28). Since the cytokines
secreted in the early phases of infection in
the experimental models of leishmaniasis
are important to determine the progression
or control of the infection, we hypothesize
that alterations in the immunological re-
sponses early in human infection may ac-
count for parasite multiplication and for clini-
cal outcome of the disease. In fact, we have
previously shown that early in the infection
(less than 60 days of disease) patients with
cutaneous leishmaniasis may present a de-
crease in IFN-γ production and an increase
in IL-10 production when compared with
patients with more than two months of dis-
ease (29). More recently, we have observed
that absent or low IFN-γ production may
occur in up to 50% of the patients with early
cutaneous leishmaniasis. To determine the
role of cytokines in modulating the immune
response in such patients, PBMC were stim-
ulated with L. amazonensis antigen in the
presence of IL-12, anti-IL-4 mAb, and anti-
IL-10 mAb. IFN-γ levels were determined
by a sandwich ELISA technique in the cul-
ture supernatants. In patients with early cu-
taneous leishmaniasis who did not have a T
cell response to Leishmania antigen, the
mean IFN-γ level in L. amazonensis-stimu-
lated PBMC supernatants was 24 – 26 pg/
ml. While the addition of anti-IL-4 mAb did
not enhance IFN-γ production (48 – 79 pg/
ml), the addition of anti-IL-10 mAb or of IL-
12 enhanced IFN-γ production to 380 – 245
and 308 – 342 pg/ml, respectively (P<0.05,
Mann-Whitney test).
The down-regulation of the immune re-
sponse in cutaneous leishmaniasis is a tran-
sitory phenomenon since virtually all pa-
tients with more than 60 days of history of
cutaneous ulcers present strong IFN-γ pro-
duction. Although this down-regulation of
IFN-γ production in the early phases of cuta-
neous leishmaniasis may account for para-
site multiplication, we have no evidence that
patients who had low IFN-γ production will
have a more severe disease measured by an
increase in ulcer size or in the number of
lesions, or dissemination of the infection. In
contrast, preliminary data from a retrospec-
tive study show that the response to pentava-
lent antimonial therapy was better in patients
with low IFN-γ production than in patients
with high IFN-γ production. A more careful
analysis of this observation is being per-
formed in a prospective study with a larger
number of patients. However, these prelimi-
nary data suggest that, although IFN-γ is
important for the control of parasite multi-
plication, it can also be involved in the patho-
genesis of the disease. One possibility is that
IFN-γ, by up-regulating TNF-α production,
may lead this pro-inflammatory cytokine to
participate in the tissue damage observed in
tegumentary leishmaniasis. In fact, TNF-α
levels are elevated in tegumentary leishman-
iasis, mainly in the severe cutaneous and
mucosal diseases (30,31). In addition, serum
TNF-α levels drop after therapy of mucosal
leishmaniasis (31).
To evaluate the role of TNF-α in the
pathology of tegumentary leishmaniasis, we
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determined TNF-α levels in PBMC superna-
tants from patients with classical cutaneous
and mucosal leishmaniasis, before and after
therapy. The TNF-α and IFN-γ levels of
patients with classical cutaneous leishmani-
asis and mucosal disease are shown in Fig-
ure 1. Both IFN-γ and TNF-α were elevated
in L. amazonensis-stimulated PBMC from
patients with cutaneous and mucosal leish-
maniasis. After successful therapy there was
a reduction in both IFN-γ and TNF-α levels
in 42% and 72% of the patients, respec-
tively. A significant reduction in TNF-α lev-
els was observed after successful therapy
(366 – 224 pg/ml before therapy vs 142 –
107 pg/ml after therapy, P = 0.02, Mann-
Whitney test) (Figure 2).
Finally, to determine if by decreasing
TNF-α levels it is possible to improve the
healing of mucosal leishmaniasis lesions,
we are performing an open study evaluating
the efficacy of pentoxifylline associated with
antimonial therapy in patients with mucosal
lesions refractory to antimonial therapy. Pen-
toxifylline is an aminoxanthine that has the
ability to decrease mRNA for TNF-α and
consequently decreases TNF-α production
(32,33). A pilot study with 6 patients with
active mucosal disease who had received at
least two courses of antimonial therapy (20
mg kg-1 day-1 for 20 days) before entering the
study was performed. The mean age of the
patients (5 men, 1 woman) was 24 – 12
years. These patients received a new course
of pentavalent antimony (Glucantime Rhodia,
20 mg/kg body weight) associated with
pentoxifylline (1.2 g/day for 20 days). The
patients were evaluated every 30 days up to
3 months and 6 and 12 months after the end
of therapy. The lesions of all patients who
received the antimonial therapy associated
with pentoxifylline healed after 30 to 60
days of therapy.
Several lines of evidence show that IFN-
γ and TNF-α are important for the control of
leishmaniasis. TNF-α plays an important
protective role in experimental murine cuta-
neous leishmaniasis (34-36) and synergizes
with IFN-γ in mediating killing of Leishma-
nia major through the induction of nitric
oxide (34). In human visceral leishmaniasis
and diffuse cutaneous leishmaniasis there is
evidence that the absence of IFN-γ allows
parasite multiplication and progression from
infection to disease (13,29). It is also ex-
pected that T cell responses and monocyte
function are important in the control of L.
braziliensis infection. In fact, there is evi-
dence of a Th1 type of response in subjects
with subclinical L. braziliensis infection and
in subjects with self-healing cutaneous leish-
maniasis (37). The observation presented
Figure 1 - TNF-α and IFN-γ levels in Leishmania antigen-stimulated PBMC from
patients with cutaneous and mucosal leishmaniasis.
Figure 2 - TNF-α and IFN-γ levels in Leishmania antigen-stimulated PBMC before
and after therapy in patients with tegumentary leishmaniasis. P = 0.02 for TNF-α
levels before and after treatment (Mann-Whitney test). Different symbols repre-
sent the patients.
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here that, early in the infection, T cell re-
sponse is depressed in cutaneous leishmani-
asis may indicate that, after infection, there
is an absence of IFN-γ production that al-
lows parasite multiplication. Later on, there
is production of IFN-γ that may control the
infection. However, an exacerbated produc-
tion of IFN-γ and TNF-α can be deleterious
for the tissue. Therefore, the present data
indicate that the same cytokines involved in
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